These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 9660111

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacological effects of venlafaxine, a new antidepressant, given repeatedly, on the alpha 1-adrenergic, dopamine and serotonin systems.
    Maj J, Rogóz Z.
    J Neural Transm (Vienna); 1999; 106(2):197-211. PubMed ID: 10226939
    [Abstract] [Full Text] [Related]

  • 3. The effect of combined treatment with imipramine and amantadine on the behavioral reactivity of central alpha1-adrenergic system in rats.
    Dziedzicka-Wasylewska M, Faron-Górecka A, Rogóz Z, Solich J.
    Behav Pharmacol; 2004 Mar; 15(2):159-65. PubMed ID: 15096916
    [Abstract] [Full Text] [Related]

  • 4. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.
    Brocco M, Dekeyne A, Papp M, Millan MJ.
    Behav Pharmacol; 2006 Nov; 17(7):559-72. PubMed ID: 17021388
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Repeated imipramine treatment enhances the 7-OH-DPAT-induced hyperactivity in rats: the role of dopamine D2 and D3 receptors.
    Rogóz Z, Skuza G.
    Pol J Pharmacol; 2001 Nov; 53(6):571-6. PubMed ID: 11985330
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of repeated treatment with reboxetine on the central alpha 1-adrenergic and dopaminergic receptors.
    Rogóz Z, Margas W, Skuza G, Solich J, Kuśmider M, Dziedzicka-Wasylewska M.
    Pol J Pharmacol; 2002 Nov; 54(6):593-603. PubMed ID: 12866714
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Some behavioural effects of antidepressant drugs are time-dependent.
    Dziedzicka-Wasylewska M, Rogóz Z, Margas W, Dlaboga D, Góralska M.
    Prog Neuropsychopharmacol Biol Psychiatry; 2001 Feb; 25(2):373-93. PubMed ID: 11294483
    [Abstract] [Full Text] [Related]

  • 11. Antidepressant drugs attenuate 7-OH-DPAT-induced hypoactivity in rats.
    Rogóz Z, Dziedzicka-Wasylewska M.
    Pol J Pharmacol; 2000 Feb; 52(5):331-6. PubMed ID: 11334224
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacological profile of reboxetine, a representative of new class of antidepressant drugs, selective noradrenaline reuptake inhibitor (NARI), given acutely.
    Rogóz Z, Wróbel A, Krasicka-Domka M, Maj J.
    Pol J Pharmacol; 1999 Feb; 51(5):399-404. PubMed ID: 10817540
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of repeated treatment with mirtazapine on the central dopaminergic D2/D3 receptors.
    Rogóz Z, Wróbel A, Dlaboga D, Dziedzicka-Wasylewska M.
    Pol J Pharmacol; 2002 Feb; 54(4):381-9. PubMed ID: 12523492
    [Abstract] [Full Text] [Related]

  • 18. Roxindole, a potential antidepressant. I. Effect on the dopamine system.
    Maj J, Kolodziejczyk K, Rogóz Z, Skuza G.
    J Neural Transm (Vienna); 1996 Feb; 103(5):627-41. PubMed ID: 8811507
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of repeated treatment with reboxetine on the central alpha1-adrenergic system.
    Rogóz Z, Kolasiewicz W.
    Pol J Pharmacol; 2001 Feb; 53(6):663-7. PubMed ID: 11985343
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.